Cipla Ltd (NSE:CIPLA) reported Q1 FY27 revenue of Rs 7,119.3 crore and net profit Rs 787.1 crore amid FY26 figures of Rs 28,162.6 crore revenue and Rs 3,869.8 crore profit, while facing tariff risk on U.S. generics, NPPA litigation, a Rs 244.37 crore labour charge and CFO resignation.Previous Week…
Q1 FY27 saw record revenue of INR 7,119 crore, with strong growth in India and North America, and robust launches in chronic and respiratory therapies. EBITDA margin was 16.7%, with guidance maintained at 18.5%-20% for FY27, contingent on new product launches. North America targets a $1 billion EBI…
Q1 FY27 saw record revenue of INR 7,119 crore, with strong growth in India and new launches driving performance. North America maintained leadership in key segments, while South Africa's private market outpaced the overall market despite tender losses. EBITDA margin guidance remains at 18.5%-20% fo…
Highest-ever Q1 revenue of INR 7,119 Cr was achieved, with strong growth in India and steady global performance. EBITDA and PAT margins declined year-over-year, but new launches in India and North America and ESG progress were notable.Original document: Cipla Ltd [CIPLA] Slides Release — Jul. 23 20…
Consolidated revenue for Q1 FY27 rose to ₹7,119.28 crore, with net profit at ₹785.55 crore. Key risks include ongoing NPPA litigation and a ₹244.37 crore exceptional item from new labour codes. Segment operations remain focused on pharmaceuticals.Original document: Cipla Ltd [CIPLA] Interim report…
